Safety data from trials In a paper summarizing 6 randomized, double-blind, placebo-controlled human trials, AOD 9604 did not significantly affect IGF-1 levels, did not impair glucose tolerance, and no serious adverse events (SAEs) were attributed to AOD 9604
While some peptides like semaglutide (a GLP-1 receptor agonist) have FDA approval for weight loss, others are available only through off-label use or experimental stages
P.PangeniR.JhaS
Contact your GP if you experience: No improvement after 46 weeks of treatment : Whilst neurological symptoms may take longer to resolve, you should notice some improvement in energy levels or general wellbeing within this timeframe
Conclusion: Healing Begins with the Gut Whether you are recovering from surgery, managing chronic inflammation, or looking to support overall wellness, gut health plays a central role
The most common causes are foods, medications, and infections